Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals
Epic: EAH
News: Latest news
Web Site: Eco Animal Health Group Plc
Other Articles: 17-03-201010-03-201002-02-2010
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday July 29, 09:30Specialist Energy Group Lays Out a Compelling Blueprint for Growth

After a difficult start to life as a stock market listed company, the company now stands at the threshold of a much brighter future. Legacy issues have been dealt with and the turnaround programme initiated by CEO Ewan Lloyd-Baker is gaining traction.

FULL ARTICLE ►
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive AU ▼

Wednesday July 28, 11:30Silver Lake Resources boosts high grade gold resource by 70% to 2.5m ounces

Silver Lake Resources has added over 1 million ounces of gold to its resource inventory during the year after mining 66,700 ounces and expects further encouraging results at its  Mount Monger and Murchison projects.

FULL ARTICLE ►
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive CN ▼

Thursday July 15, 02:10Henan Yuguang Lead & Gold investment in Kimberley Metals receives all clear from FIRB

Kimberley Metals (ASX: KBL) has reported that on 12 July the Australian Government Foreign Investment Review Board (FIRB) had no objections to Henan Yuguang Lead & Gold Co. Ltd's [...]

FULL ARTICLE ►
Eco Animal Health Group Plc

Eco Animal Health Group Plc

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

CLICK HERE FOR FULL ANLAYSIS OF ECO ANIMAL HEALTH GROUP PLC
Wednesday, March 17, 2010

ECO Animal Health forms North America distribution JV

company news image

ECO Animal Health Group PLC (AIM: EAH) said ECO Animal Health Ltd has formed a joint venture with Pharmgate LLC of Ramsey, New Jersey, aimed at distributing the partners’ veterinary products in the North American livestock and poultry markets.

Pharmgate is the wholly-owned US subsidiary of Jinhe Biotechnology Ltd of China.

The venture is called Pharmgate Animal Health LLC and will benefit from the manufacturing and product development experience of its owners to bring to market their ranges of extensively used medicated feed additives and new therapeutic compounds for livestock and poultry, backed by a specialist sales and technical team.

ECO Animal Health Group CEO Marc Loomes said: "This is an important step in the global commercialisation of Aivlosin, our novel antibiotic for the treatment of enteric and respiratory disease in swine and poultry. Pre-approval studies in the US market have shown similar performance of Aivlosin to that seen in markets where the product is already being successfully sold, including Europe, Central and Latin America, China, Japan, South East Asia and Africa.”

Pharmgate general manager Colin Gray commented: “Our FDA-approved (Food and Drug Administration) manufacturing facilities in China meet the highest international quality, safety and environmental standards and are well-known to the industry. We look forward to satisfying our customers' requirements for a streamlined, no-nonsense source of key animal health products.”

ECO Animal Health Group develops, registers and markets pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel macrolide antibiotic, Aivlosin, as well as a range of generic therapeutic products.

Jinhe Biotechnology Co produces chlortetracycline feed grade, chlortetracycline hydrochloride, salinomycin and other animal health compounds. The company has marketing or supply approvals for these products in most major markets throughout the world.

AddThis Feed Button
Register here to be notified of future Eco Animal Health Group Plc articles.


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.